

Translational control of the activation of transcription factor NF- κ B and production of type I interferon by phosphorylation of the translation factor eIF4E

Barbara Herdy^{1,11}, Maritza Jaramillo^{1,11}, Yuri V Svitkin¹, Amy B Rosenfeld¹, Mariko Kobayashi², Derek Walsh³, Tommy Alain¹, Polen Sean¹, Nathaniel Robichaud¹, Ivan Topisirovic¹, Luc Furic⁴, Ryan J O Dowling¹, Annie Sylvestre¹, Liwei Rong⁵, Rodney Colina⁶, Mauro Costa-Mattioli⁷, Jörg H Fritz⁸, Martin Olivier⁹, Earl Brown¹⁰, Ian Mohr² & Nahum Sonenberg¹

Type I interferon is an integral component of the antiviral response, and its production is tightly controlled at the levels of transcription and translation. The eukaryotic translation-initiation factor eIF4E is a rate-limiting factor whose activity is regulated by phosphorylation of Ser209. Here we found that mice and fibroblasts in which eIF4E cannot be phosphorylated were less susceptible to virus infection. More production of type I interferon, resulting from less translation of *Nfkb1* mRNA (which encodes the inhibitor I κ B α), largely explained this phenotype. The lower abundance of I κ B α resulted in enhanced activity of the transcription factor NF- κ B, which promoted the production of interferon- β (IFN- β). Thus, regulated phosphorylation of eIF4E has a key role in antiviral host defense by selectively controlling the translation of an mRNA that encodes a critical suppressor of the innate antiviral response.

The host innate immune system is the first line of defense against invading pathogens, which encompasses viruses¹. Type I interferon, which includes interferon- α (IFN- α) and IFN- β , is a pivotal component of this system. Rapid synthesis and secretion of these cytokines is crucial for a potent antiviral and immunomodulatory response. The initial induction of type I interferon is dependent on the recognition of pathogens by pattern-recognition receptors, which survey the extracellular and intracellular milieu. DNA and RNA viruses are recognized by pattern-recognition receptors, including Toll-like receptors, present on the cell surface and in endosomes, as well as several cytoplasmic receptors². The presence of a virus triggers a cascade of events that ultimately results in the activation of several transcription factors, including IRF3, IRF7, ATF2-c-Jun and NF- κ B. Those factors, together with the transcription factor IRF1, the transcriptional coactivators CBP and p300 and the architectural protein HMGI(Y), form the IFN- β enhanceosome, which activates transcription of the gene encoding IFN- β (*Ifnb1*)³. The NF- κ B pathway is particularly crucial in the control of various arms of the innate immune response and is phylogenetically conserved from insects to vertebrates⁴. Under basal conditions, the short-lived inhibitor I κ B α binds to NF- κ B in the cytoplasm, which prevents translocation of

NF- κ B to the nucleus and subsequent activation of transcription⁵. After infection with a virus or stimulation with tumor necrosis factor, type I interferon or the synthetic RNA duplex poly(I:C), I κ B α is phosphorylated by I κ B kinases, which results in ubiquitination of I κ B α and its degradation by the proteasome⁶. NF- κ B then translocates to the nucleus and facilitates transcription of NF- κ B-regulated genes, including *Ifnb1* (ref. 7). The synthesis of most components of the type I interferon pathway, including regulators and interferon itself, requires stringent control, which is accomplished at transcriptional and translational levels^{8,9}.

Translational control enables the cell to instantly adjust to its environment by regulating the translation rate of select mRNAs. It is thus ideally suited for the rapid responses required for host defense against viruses, which must utilize the cellular translation machinery to produce viral proteins. Under most circumstances, translational control is exerted at the initiation step, at which the ribosome is recruited to the 5' end of an mRNA bearing the cap structure m⁷GpppN (where 'm⁷' indicates 7-methylguanosine, 'ppp' indicates triphosphate and 'N' is any nucleotide). The interaction between the ribosome and the mRNA is facilitated by the heterotrimeric eIF4F complex that consists of eIF4E, which directly binds the mRNA 5'-cap structure;

¹Department of Biochemistry and Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada. ²Department of Microbiology and NYU Cancer Institute, New York University School of Medicine, New York, New York, USA. ³National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland. ⁴Department of Anatomy and Developmental Biology, Monash University, Clayton, Australia. ⁵McGill AIDS Center, Lady Davis Institute of the Jewish General Hospital, Montreal, Canada. ⁶Laboratorio de Virologia Molecular, Regional Norte-Salto, Universidad de la República, Salto, Uruguay. ⁷Department of Neuroscience, Baylor College of Medicine, Houston, Texas, USA. ⁸Complex Traits Group and Department of Microbiology and Immunology, McGill University, Montreal, Canada. ⁹The Research Institute of the McGill University Health Centre, Centre for the Study of Host Resistance, Department of Medicine and Department of Microbiology and Immunology, McGill University, Montreal, Canada. ¹⁰Department of Biochemistry, Microbiology and Immunology, and Emerging Pathogens Research Centre, University of Ottawa, Ottawa, Canada. ¹¹These authors contributed equally to this work. Correspondence should be addressed to N.S. (nahum.sonenberg@mcgill.ca).

Received 24 January; accepted 19 March; published online 29 April 2012; doi:10.1038/ni.2291




Figure 1 Replacement of the serine at the eIF4E-phosphorylation site at position 209 with alanine impairs VSV replication. **(a)** Immunoblot analysis of VSV glycoprotein (G), nucleocapsid protein (N) and phosphoprotein (P), as well as β -actin (loading control throughout) and eIF4E, in lysates of wild-type and eIF4E(S209A) MEFs mock infected (0) or infected for 2–10 h (above lanes) with VSV at a multiplicity of infection of 1 plaque-forming unit (PFU) per cell. **(b)** Cytopathic effect of VSV in wild-type and eIF4E(S209A) MEFs at 10 h after infection as in **a**. Original magnification, $\times 10$. **(c)** Plaque assay of VSV titers 10 h after infection as in **a**. **(d)** Immunoblot analysis of VSV proteins (as in **a**), β -actin, total eIF4E and phosphorylated (p-) eIF4E in lysates of eIF4E(S209A) MEFs transfected with empty vector (EV) or vector encoding wild-type eIF4E, mock infected (0) or infected for 20 h with VSV at a multiplicity of infection (MOI) of 0.01 PFU/cell. **(e)** Plaque assay of VSV titers in eIF4E(S209A) MEFs transfected and infected as in **d**. Data are representative of three independent experiments (error bars, s.e.m.).

eIF4G, a scaffolding protein; and eIF4A, a DEAD-box RNA helicase¹⁰. The subunit eIF4G interacts with eIF3, which is bound to the small ribosomal subunit, thereby establishing the critical link between the mRNA and the ribosome.

Among translation-initiation factors, eIF4E is the least abundant, and it is thought to be limiting for translation¹¹. Thus, regulating eIF4E activity is critical for cellular function. The mitogen-activated protein kinase–interacting kinases Mnk1 and Mnk2 phosphorylate Ser209 of eIF4E¹². Although the function of eIF4E phosphorylation in various biological contexts remains unclear, it has been shown to control the translation of certain mRNAs that encode proteins associated with inflammation and cancer¹³. Mnk1 and Mnk2 are the sole kinases known to phosphorylate eIF4E in mice¹⁴. Although Mnk2 is constitutively active, Mnk1 is regulated by signaling cascades of the mitogen-activated protein kinases p38 and Erk in response to mitogens, growth factors and hormones^{15,16}.

Phosphorylation of eIF4E is altered during viral infection. Dephosphorylation of eIF4E occurs during infection with influenza virus, adenovirus, encephalomyocarditis virus (EMCV), poliovirus or vesicular stomatitis virus (VSV)^{17–20}. In contrast, infection with herpesvirus or poxvirus stimulates Mnk1-dependent phosphorylation of eIF4E^{21–24}. Although inhibition of Mnk1 suppresses the replication of herpesvirus and poxvirus^{21–24}, direct involvement of eIF4E phosphorylation in infection by DNA viruses has not been established. Furthermore, it is unclear how dephosphorylation of eIF4E affects the replication of RNA viruses. To address those issues, we studied mouse embryonic fibroblasts (MEFs) derived from mice in which the serine at position 209 of eIF4E was replaced with alanine (eIF4E(S209A) mice), which prevented phosphorylation of eIF4E at this critical regulatory site. We found that loss of eIF4E phosphorylation in eIF4E(S209A) mice and cells resulted in an enhanced type I interferon immune response that protected against viral infection. We also found that the phosphorylation status of eIF4E controlled IFN- β production by regulating the translation of *Nfkb* mRNA, which encodes I κ B α , the repressor of NF- κ B. Impaired infection of eIF4E(S209A) cells with select RNA or DNA viruses demonstrated direct involvement of eIF4E phosphorylation in viral pathogenesis and host defense.

RESULTS

Impaired VSV replication in cells lacking eIF4E phosphorylation

To understand how the phosphorylation of eIF4E affects the replication of VSV, a negative-stranded RNA virus, we used spontaneously

immortalized MEFs derived from wild-type or eIF4E(S209A) mice¹³. VSV-encoded mRNAs are translated via a cap-dependent mechanism²⁵. By immunoblot analysis, we detected strong signals for most viral proteins in wild-type MEFs at 10 h after infection but detected only small amounts of VSV-specific glycoprotein, nucleocapsid protein and phosphoprotein in eIF4E(S209A) MEFs (**Fig. 1a**). To exclude the possibility that the lower abundance of viral proteins in infected eIF4E(S209A) MEFs was a consequence of impaired global protein synthesis, we determined that new protein synthesis in uninfected eIF4E(S209A) MEFs was similar to that in wild-type MEFs (**Supplementary Fig. 1a**). In contrast to infected wild-type MEFs, infected eIF4E(S209A) cells did not show a detectable cytopathic effect (**Fig. 1b**). Plaque assays showed a $\sim 1,000$ -fold higher viral yield in wild-type MEFs than in eIF4E(S209A) MEFs (**Fig. 1c**). The inhibition of VSV replication in eIF4E(S209A) MEFs was independent of the genetic background of the host, as we observed less abundance of viral proteins in eIF4E(S209A) MEFs from either C57BL/6 mice (**Supplementary Fig. 1b**) or BALB/c mice (**Supplementary Fig. 1c**). To confirm that the lower susceptibility of eIF4E(S209A) MEFs to VSV infection was a consequence of the S209A substitution rather than an unintended consequence of the gene-targeting manipulation, we reintroduced a gene encoding wild-type eIF4E into eIF4E(S209A) MEFs. Expression of wild-type eIF4E in eIF4E(S209A) MEFs enhanced VSV replication, as shown by more accumulation of viral protein (**Fig. 1d**) and more production of infectious virus (**Fig. 1e**). These data demonstrated that the impaired replication of VSV in eIF4E(S209A) MEFs was directly associated with the mutated *Eif4e* allele encoding the S209A substitution that precludes eIF4E phosphorylation.

Substitution of the serine at position 209 with phosphomimetic glutamic or aspartic acid residues does not recapitulate the activity of wild-type eIF4E. Phosphomimetic mutants of eIF4E have less cap-binding ability²⁶, less ability to transport mRNA and substantially attenuated ability to transform cells^{27,28}. Thus, these mutants do not mimic phosphorylated serine and therefore could not be used to show that the restricted replication of VSV in eIF4E(S209A) MEFs resulted from the inability of eIF4E to be phosphorylated rather than from nonspecific effects of the S209A substitution. Thus, we used MEFs deficient in the eIF4E kinases Mnk1 and Mnk2 to study this. Phosphorylation of eIF4E is not observed in cells that lack both kinases¹⁴. We obtained spontaneously immortalized MEFs derived from wild-type mice and mice doubly deficient in both Mnk1 and Mnk2 (Mnk1-Mnk2-deficient) and infected these MEFs with VSV. As noted for eIF4E(S209A) cells, accumulation of VSV protein was




Figure 2 Restricted viral protein synthesis in eIF4E(S209A) MEFs infected with Sindbis virus or EMCV. **(a)** Autoradiogram (top) of new protein synthesis in wild-type and eIF4E(S209A) MEFs pulse-labeled with [35 S]methionine and mock infected (0) or infected for 17 h with Sindbis virus (SV; MOI above lanes); left margin, viral proteins. Below, immunoblot analysis (IB) of total and phosphorylated eIF4E and β -actin. **(b)** Autoradiogram of wild-type and eIF4E(S209A) MEFs pulse-labeled with [35 S]methionine, deprived of serum for 72 h and mock-infected or infected for 4, 5 or 6 h (above lanes) with EMCV (MOI, 10 PFU/cell); left margin, viral proteins. Data are representative of three independent experiments.

considerably impaired in infected Mnk1-Mnk2-deficient MEFs (Supplementary Fig. 2a). Although we detected a pronounced cytopathic effect in infected wild-type cells, Mnk1-Mnk2-deficient MEFs remained unaffected (Supplementary Fig. 2b). In sum, these results suggested that precluding phosphorylation of eIF4E via the S209A substitution or by deletion of eIF4E kinases impeded the replication of VSV.

Impaired replication of RNA viruses in eIF4E(S209A) cells

To investigate whether the replication of other RNA viruses was similarly impaired in eIF4E(S209A) MEFs or if the replication defect was specific to VSV, we infected wild-type and eIF4E(S209A) MEFs with the alphavirus Sindbis virus or with the picornavirus EMCV. Sindbis virus-encoded mRNA has a 5'-cap structure and is translated in an eIF4E-dependent manner²⁹, similar to that of VSV²⁵. EMCV mRNA lacks a 5'-cap structure and is translated in an eIF4E-independent manner via an internal ribosome entry site³⁰. Infection of eIF4E(S209A) MEFs with Sindbis virus or EMCV resulted in less production of viral protein than did infection of wild-type MEFs, as determined by metabolic labeling with [35 S]methionine (Fig. 2a,b). Because translation of EMCV proteins is cap independent, these results suggested that the diminished replication of EMCV in eIF4E(S209A) MEFs was probably a consequence

of translational changes in host mRNA(s) whose protein product(s) is (are) essential for the regulation of virus infection.

Production of more type I interferon in eIF4E(S209A) cells

To determine if the diminished virus replication in eIF4E(S209A) cells could have been due to enhanced production of type I interferon, we treated wild-type and eIF4E(S209A) MEFs with poly(I:C), a potent inducer of type I interferon (Supplementary Fig. 3a). We grew naive wild-type MEFs in control medium or in the presence of conditioned medium from poly(I:C)-treated wild-type or eIF4E(S209A) cells and then infected the MEFs with VSV. Control medium from mock-treated eIF4E(S209A) cells resulted in a VSV yield \sim 1,300-fold higher than that resulting from conditioned medium from poly(I:C)-treated eIF4E(S209A) cells (Fig. 3a), whereas control medium from wild-type cells resulted in a VSV yield only twofold higher than that resulting from conditioned medium from poly(I:C)-treated wild-type cells (Fig. 3a). Thus, conditioned medium from poly(I:C)-treated eIF4E(S209A) cells had potent antiviral activity.

To investigate whether IFN- β production was responsible for the antiviral activity detected, we used semiquantitative RT-PCR to measure *Ifnb1* mRNA. Stimulation of eIF4E(S209A) MEFs for 6 h with poly(I:C) produced approximately 12-fold more *Ifnb1* mRNA than did stimulation of wild-type cells (Fig. 3b). We also detected much more *Iflh1* mRNA (which encodes the RNA helicase Mda5) and *Irf7* mRNA (which encodes the transcription factor IRF7), whose transcription is induced by type I interferon and whose protein products are required for poly(I:C)-dependent induction of IFN- β ^{31,32}, after treatment of eIF4E(S209A) MEFs with poly(I:C) (\sim 16-fold for *Irf7* mRNA and \sim 4-fold for *Iflh1* mRNA; Fig. 3b), whereas secretion of IFN- β was sixfold greater from eIF4E(S209A) MEFs than from wild-type cells (Fig. 3c). These data demonstrated that eIF4E(S209A) MEFs produced more IFN- β .

To show that the greater abundance of IFN- β in the medium of infected eIF4E(S209A) MEFs antagonized viral replication, we cultured cells in the presence of neutralizing antibodies to type I interferon before and during VSV infection. The addition of antibody to IFN- β (anti-IFN- β) alone or in combination with anti-IFN- α enhanced the accumulation of VSV protein (Fig. 4a) and viral titers (Fig. 4b) in eIF4E(S209A) MEFs, albeit not to the same degree observed in wild-type MEFs (21% of wild type). The amount of anti-IFN- β used (25 μ g/ml) was sufficient to neutralize the secreted IFN- β , as we found that a concentration of this antibody as low as 0.25 μ g/ml was saturating for the enhancement of VSV replication (Supplementary Fig. 3b). In addition, in EMCV-infected wild-type and eIF4E(S209A) MEFs, control rat immunoglobulin G or isotype-matched monoclonal antibody to IFN- γ did not cause more replication of EMCV, whereas the addition of anti-IFN- β enhanced EMCV viral

Figure 3 More production of type I interferon in eIF4E(S209A) MEFs after poly(I:C) stimulation.

(a) VSV titers in naive wild-type MEFs grown overnight in the presence of conditioned medium from wild-type or eIF4E(S209A) cells left untreated (–) or treated for 6 h (+) with poly(I:C) (0.5 μ g/ml); after that overnight incubation, MEFs were infected for 12 h with VSV (MOI, 0.1 PFU/cell). **(b)** Semiquantitative RT-PCR of *Ifnb1*, *Iflh1* and *Irf7* mRNA among total RNA isolated from wild-type and eIF4E(S209A) MEFs treated for 6 h with various concentrations (above lanes) of poly(I:C). *Actb* encodes β -actin (loading control). **(c)** Enzyme-linked immunosorbent assay of IFN- β in conditioned medium of wild-type and eIF4E(S209A) MEFs treated for 6 h with various concentrations (horizontal axis) of poly(I:C). Data are representative of two independent experiments (error bars, s.e.m.).





Figure 4 The addition of neutralizing antibody to IFN- β enhances viral replication in eIF4E(S209A) MEFs. **(a)** Immunoblot analysis of VSV proteins in lysates of wild-type and eIF4E(S209A) MEFs mock treated or treated with anti-IFN- β (25 μ g/ml) alone or in combination anti-IFN- α (20 μ g/ml), followed by infection for 12 h with VSV (MOI, 0.1 PFU/cell). **(b)** VSV titers in wild-type and eIF4E(S209A) MEFs infected for 12 h with VSV (MOI, 0.1 PFU/cell) in the presence or absence of neutralizing anti-IFN- β and anti-IFN- α . **(c)** EMCV titers in wild-type and eIF4E(S209A) MEFs (2×10^5) deprived of serum (0.5% FBS in DMEM) for

72 h, then treated for 24 h with control antibody (rat immunoglobulin G (IgG); 2.5 μ g/ml) or neutralizing anti-IFN- β or anti-IFN- γ and then infected for 48 h with EMCV (100 PFU). Data are representative of two **(a)** or three **(b,c)** independent experiments (error bars, s.e.m.).



titers by ~100-fold (Fig. 4c). Thus, eIF4E(S209A) MEFs produced and secreted more IFN- β than did wild-type MEFs and this greater production of type I interferon in eIF4E(S209A) cells antagonized the replication of two different RNA viruses.

Lower susceptibility of eIF4E(S209A) mice to VSV infection

To assess the susceptibility of eIF4E(S209A) mice to infection with VSV, we infected female wild-type and eIF4E(S209A) mice intranasally with VSV and monitored the mice for 12 d. In this model, VSV is neurovirulent and results in fatal encephalitis, which is preceded by hindlimb paralysis. Although only ~50% of the wild-type mice survived this infection, 87% of the eIF4E(S209A) mice survived this infection ($P = 0.0243$; Fig. 5a). Wild-type mice secreted less type I interferon into the serum than did eIF4E(S209A) mice at 48 h after infection ($P = 0.0507$; Fig. 5b). These data established that eIF4E(S209A) mice produced more type I interferon in response to viral infection than did wild-type mice and were more resistant to the neurovirulent effects of infection with VSV.

Less translation of *Nfkb* mRNA in eIF4E(S209A) cells

To investigate the molecular mechanism by which the production of type I interferon was enhanced in eIF4E(S209A) MEFs, we used genome-wide polysome analysis to compare wild-type and

eIF4E(S209A) MEFs¹³. Notably, *Nfkb* mRNA was one of the mRNAs whose translation was lower in eIF4E(S209A) MEFs than in wild-type cells and was the only mRNA that encodes a protein conspicuously involved in signaling pathways that regulate the expression of type I interferon. I κ B α inhibits NF- κ B, which is an essential nuclear factor in the activation of transcription³. A lower abundance of I κ B α in eIF4E(S209A) cells would thus be expected to result in more translocation of NF- κ B to the nucleus. The amount of I κ B α in eIF4E(S209A) MEFs was approximately 50% of that in wild-type cells, as determined by immunoblot analysis (Fig. 6a). Ribosome loading of *Nfkb* mRNA was much lower in eIF4E(S209A) MEFs, as indicated by the prominent shift of *Nfkb* mRNA toward lighter polysomal fractions (fractions 3–5 in eIF4E(S209A) MEFs, compared with fractions 6–9 in wild-type MEFs; Fig. 6b). This indicated that initiation of the translation of *Nfkb* mRNA was lower in eIF4E(S209A) MEFs than in wild-type MEFs. In contrast, we detected no apparent change in the polysome distribution of 'eIF4E-insensitive' *Actb* mRNA (which encodes β -actin; Fig. 6b). Cap-dependent translation of VSV mRNA that encodes the virus matrix protein and translation of luciferase reporter mRNA driven by an EMCV internal ribosome entry site were not diminished by the eIF4E(S209A) substitution, as determined by polysome profiling (Supplementary Fig. 4a–c) and luciferase assay (Supplementary Fig. 4d). In addition, depletion of I κ B α through the use of short hairpin RNA (shRNA) in wild-type MEFs diminished VSV replication (Fig. 6c,d), which provided evidence that lowering the amount of I κ B α was sufficient to diminish the production of VSV protein and VSV replication. Together these data demonstrated that translation of *Nfkb* mRNA was selectively impaired as a consequence of dephosphorylation of eIF4E, which resulted in less I κ B α protein.

More NF- κ B activity in eIF4E(S209A) cells

Less I κ B α in eIF4E(S209A) MEFs would be expected to result in enhanced NF- κ B activity^{6,7}. We used electrophoretic mobility-shift assay (EMSA) to monitor site-specific DNA-binding activity of NF- κ B in nuclear extracts of wild-type and eIF4E(S209A) MEFs and detected more NF- κ B activity in nuclear extracts of eIF4E(S209A) MEFs than in those of wild-type MEFs under basal conditions (Fig. 6e). We observed an increase in the binding of NF- κ B to DNA in nuclear protein extracts of wild-type and eIF4E(S209A) cells at 15 and 30 min after incubation with tumor necrosis factor, a potent inducer of NF- κ B. However, the increase was greater in extracts of eIF4E(S209A) MEFs than in those of wild-type MEFs. As a control, we determined that binding of the transcription factors SP1 and AP-1 to DNA was similar in extracts of wild-type and eIF4E(S209A) cells (Fig. 6e). The difference between wild-type and eIF4E(S209A)





Figure 5 Enhanced survival of eIF4E(S209A) mice after intranasal infection with VSV. **(a)** Survival of female wild-type mice ($n = 14$) and eIF4E(S209A) mice ($n = 17$) infected intranasally with VSV (1×10^4 PFU/mouse) and monitored for 12 d (mice were killed when they developed hindlimb paralysis); results are presented as a Kaplan-Meier plot. $P = 0.0243$ (Mantel-Cox test). **(b)** Concentration of IFN- β in blood from wild-type mice ($n = 8$) and eIF4E(S209A) mice ($n = 7$) infected for 48 h with VSV (1×10^4 PFU/mouse). Each symbol represents an individual mouse; small horizontal lines indicate the mean. $*P = 0.0507$ (t -test). Data are representative of two independent experiments.

Figure 6 Less translation of *Nfkb* mRNA in eIF4E(S209A) MEFs leads to more activation of NF- κ B. (a) Immunoblot analysis of I κ B α , total and phosphorylated eIF4E, and β -actin in wild-type and eIF4E(S209A) MEFs deprived of serum overnight and then stimulated with serum as described¹³. (b) Polysome profiles of wild-type and eIF4E(S209A) MEFs (top left); semiquantitative RT-PCR analysis of cytoplasmic *Actb* and *Nfkb* mRNA among total RNA isolated from wild-type and eIF4E(S209A) cells (top right); and distribution of ribosomal RNA in individual fractions collected after sucrose-gradient (10–50%) centrifugation of cytoplasmic extracts of wild-type and eIF4E(S209A) MEFs, with semiquantitative RT-PCR analysis of the distribution of *Nfkb* and *Actb* mRNA (bottom). Results for polysome profiles are presented as absorbance at 254 nm (A_{254}); 40S, 60S and 80S indicate ribosomal subunits. (c) Immunoblot analysis of I κ B α and β -actin in extracts of wild-type MEFs transfected with vector for control (Ctrl) shRNA or shRNA targeting I κ B α . (d) Immunoblot analysis of VSV proteins, total and phosphorylated eIF4E, and β -actin in lysates of wild-type MEFs transfected with vector for control or I κ B α -specific shRNA and mock infected (0) or infected for 17 h with VSV (MOI, above lanes). (e) EMSA of NF- κ B subunits RelA and p50, as well as of SP1 and AP-1 (controls), in nuclear extracts of wild-type and eIF4E(S209A) MEFs treated for 0, 15 or 30 min (above lane) with tumor necrosis factor (TNF; 1 ng/ml). Data are representative of two independent experiments.



MEFs in the formation of the NF- κ B–DNA complex was due to lack of eIF4E phosphorylation in eIF4E(S209A) cells, as the expression of wild-type eIF4E in these cells resulted in 44% less DNA-binding activity of NF- κ B (Supplementary Fig. 5a). In addition, through the use of an NF- κ B-specific reporter plasmid, we confirmed that eIF4E(S209A) MEFs had more NF- κ B transcriptional activity under basal conditions (Supplementary Fig. 5b). Consistent with those results, expression of the NF- κ B target genes *Ccl11* (ref. 33) and *Il1b*³⁴ was enhanced 4-fold and 139-fold, respectively, in untreated eIF4E(S209A) MEFs relative to their expression in wild-type cells (Supplementary Fig. 5c). However, the greater abundance of IL-1 β did not contribute to the antiviral effect detected in eIF4E(S209A) MEFs (Supplementary Fig. 6a,b). Thus, eIF4E(S209A) MEFs had

greater NF- κ B activity than did wild-type MEFs, which resulted in enhanced induction of NF- κ B target genes.

To show that the greater abundance of IFN- β was due to enhanced transcription via NF- κ B, we transfected luciferase reporter plasmids containing the complete mouse *Irfn1* promoter or the positive regulatory domain II (PRDII), which is a distinct part of the *Irfn1* promoter that shares 80% nucleotide homology with the binding site for NF- κ B, into eIF4E(S209A) and wild-type MEFs. We observed more luciferase activity for each promoter in eIF4E(S209A) MEFs than in wild-type MEFs (Supplementary Fig. 7a,b), which suggested that the greater production of IFN- β in eIF4E(S209A) MEFs was caused by transcriptional activation of *Irfn1*. We detected no difference between wild-type and eIF4E(S209A) MEFs in the translation




Figure 7 Less translation of *Nfkb* transcripts in wild-type MEFs infected with VSV or EMCV. (a) Polysome profiles (as in Fig. 6b) of wild-type MEFs mock infected or infected for 8 h with VSV (MOI, 1 PFU/cell; left), and semiquantitative RT-PCR analysis of cytoplasmic *Actb* and *Nfkb* mRNA among total RNA isolated from mock-infected (–) or VSV-infected (+) wild-type MEFs (right, top) and of the distribution of *Nfkb* and *Actb* mRNA in fractions (collected as in Fig. 6b) of cytoplasmic extracts of mock-infected (WT) or VSV-infected (WT + VSV) wild-type MEFs (right, below). (b) Polysome profiles (as in Fig. 6b) of wild-type MEFs mock infected or infected for 6 h with EMCV (MOI, 0.1 PFU/cell) in medium supplemented with 2% serum (left), and semiquantitative RT-PCR analysis of cytoplasmic *Actb* and *Nfkb* mRNA among total RNA from mock- or EMCV-infected wild-type MEFs (right, top) and of the distribution of *Nfkb* and *Actb* mRNA in fractions (collected as in Fig. 6b) of cytoplasmic extracts of mock- or EMCV-infected wild-type MEFs (right, below). (c) EMSA of NF- κ B in nuclear extracts of wild-type MEFs infected for 0–10 h (above lanes) with VSV (MOI, 1 PFU/cell; top), and immunoblot analysis of VSV proteins, β -actin and total and phosphorylated eIF4E in cytoplasmic extracts of those cells (below). (d) EMSA of NF- κ B in nuclear extracts of lungs from wild-type mice mock infected (0) or infected for 16 h with VSV (2×10^6 PFU/mouse); each lane is extracts from the lung of one mouse. Data are representative of two independent experiments.




Figure 8 Less replication of DNA viruses in eIF4E(S209A) MEFs. (a) Immunoblot analysis of proteins from vaccinia virus (VV) in lysates of wild-type and eIF4E(S209A) MEFs (4×10^5) infected for 64 h with vaccinia virus (300 or 3,000 PFU). (b) Isoelectric focusing of total proteins from **a** and immunoblot analysis of eIF4E; arrow indicates phosphorylated eIF4E. (c) Vaccinia virus titers in wild-type and eIF4E(S209A) MEFs (4×10^5) infected for 64 h with vaccinia virus (300 PFU). (d) Phase-contrast images (left) and fluorescence images of Hoechst staining (middle) and green fluorescent protein (GFP; right) of wild-type and eIF4E(S209A) MEFs infected with an HSV-1 strain expressing enhanced green fluorescent protein fused to the late viral protein Us11. Original magnification, $\times 20$. Data are representative of three independent experiments (error bars, s.e.m.).

of *Ifnb1* mRNA (**Supplementary Fig. 4c**). Together these data indicated that phosphorylation of eIF4E modulated the type I interferon response by controlling the translation of *Nfkb* mRNA and, subsequently, the activation of NF- κ B.

Virus-induced eIF4E dephosphorylation and NF- κ B activation

To demonstrate the physiological importance of the dephosphorylation of eIF4E, we assessed the translation of *Nfkb* mRNA in wild-type MEFs infected with viruses (VSV or EMCV) known to dephosphorylate eIF4E^{19,20}. Ribosomal loading of *Nfkb* mRNA was much lower in VSV-infected wild-type MEFs than in uninfected wild-type MEFs, as indicated by the shift of *Nfkb* mRNA toward lighter polysomal fractions (**Fig. 7a**, fractions 11–12). We obtained similar results with wild-type cells infected with EMCV (**Fig. 7b**, fractions 8–10). In addition, VSV infection resulted in the activation of NF- κ B in wild-type cells (**Fig. 7c**) and wild-type mice (**Fig. 7d**). These results suggested that the cellular antiviral response to RNA viruses that induce dephosphorylation of eIF4E involved less translation of *Nfkb* mRNA and activation of NF- κ B.

We next sought to determine whether infection with DNA viruses would result in a similar phenotype. We infected wild-type and eIF4E(S209A) MEFs with the following two DNA viruses known to stimulate phosphorylation of eIF4E: vaccinia virus (a poxvirus) and herpes simplex virus 1 (HSV-1; a member of the herpesviridae)^{21,22}. The replication of vaccinia virus (**Fig. 8a–c**) and HSV-1 (**Fig. 8d**) was

impaired in eIF4E(S209A) MEFs relative to their replication in wild-type cells. Hence, absence of the eIF4E-phosphorylation site Ser209 resulted in less replication of DNA and RNA viruses in MEFs, which demonstrated that this post-translational modification of eIF4E acted as a determinant of host susceptibility to a broad spectrum of viruses.

DISCUSSION

The production of type I interferon is critical in the innate host response to limit viral replication. A key cellular component that regulates the production of type I interferon is the transcriptional activator NF- κ B^{3,35}. Here we have established that activation of NF- κ B was regulated by a mechanism that involved phosphorylation of the cap-binding protein eIF4E. Translation of the mRNA encoding I κ B α , the short-lived inhibitor of NF- κ B, was selectively lower in MEFs from mice with the S209A substitution of eIF4E that prevents eIF4E phosphorylation. Less I κ B α resulted in more activated NF- κ B in eIF4E(S209A) cells, which in turn enhanced the production of type I interferon. Not only was the replication of three different RNA viruses impaired in eIF4E(S209A) MEFs but also eIF4E(S209A) mice were more resistant to the neurological damage caused by VSV infection. Together our results have demonstrated a key role for the phosphorylation of eIF4E in viral pathogenesis and host defense against VSV through its effect on the translation of mRNA that encodes a critical suppressor of the innate antiviral response.

The production of IFN- β is dependent on several transcription factors, including NF- κ B, that assemble on the DNA at a region immediately upstream of the *Ifnb1* promoter to form the IFN- β enhanceosome^{3,7,36}. As the enhanceosome components exist in sub-optimal concentrations in a cell, many cells do not produce IFN- β . Only 20% of an infected cell population reportedly expresses *Ifnb1* mRNA^{37,38}. Diminishing the abundance of phosphorylated eIF4E provides a means for rapidly increasing NF- κ B activity and thereby promoting assembly of the IFN- β enhanceosome, especially in cells that would otherwise fail to activate *Ifnb1* transcription. The existence of virus-encoded proteins, including the poliovirus protein 3C, which cleaves the RelA subunit of NF- κ B³⁹ and the influenza virus protein NS1, which prevents the activation of NF- κ B mediated by double-stranded RNA⁴⁰, further illustrates the importance of neutralizing NF- κ B-mediated production of type I interferon for efficient propagation of virus.

Diminishing the abundance of phosphorylated eIF4E promoted the activation of NF- κ B and production of type I interferon by inhibiting the translation of *Nfkb* mRNA. Notably, dephosphorylation of eIF4E occurs late in infection with several viruses^{19,20}. Our data have suggested that dephosphorylation of eIF4E enabled cells to rapidly produce type I interferon via a translational-control mechanism that selectively diminished I κ B α and stimulated activation of NF- κ B. Although this would be of limited benefit to the cell during the first cycle of viral replication, it could effectively establish an antiviral state in the surrounding cells. Thus, diminishing the phosphorylation of eIF4E might be a cellular response aimed at limiting the spread of viral infection and protecting the host.

Although enhanced production of type I interferon was the main mechanism that rendered eIF4E(S209A) MEFs more resistant to infection with RNA viruses, the production and secretion of other antiviral cytokines might also be involved, as the addition of neutralizing antibody to IFN- β to infected eIF4E(S209A) MEFs failed to fully restore VSV replication. Even unstimulated eIF4E(S209A) MEFs secreted more of the NF- κ B-dependent cytokines CCL11 (eotaxin) and IL-1 β than did wild-type MEFs. CCL11 (eotaxin) is a chemokine

known to attract eosinophils, and IL-1 β is a proinflammatory cytokine that mediates a wide range of immune and inflammatory responses. Despite the enhanced secretion of IL-1 β from eIF4E(S209A) cells, neutralization of IL-1 β in combination with neutralization of IFN- β did not render eIF4E(S209A) MEFs more susceptible to VSV infection. That observation further demonstrated that IFN- β was the main cytokine that limited viral replication in eIF4E(S209A) MEFs. Systemically, however, secretion of these cytokines could further augment the antiviral phenotype observed in eIF4E(S209A) mice, as recruitment of several cells of the immune response to the site of infection could clear the virus more effectively.

Viruses use various strategies to attenuate the type I interferon response. Indeed, both herpesvirus and poxvirus produce proteins that stimulate the assembly of eIF4F and promote the phosphorylation of eIF4E, which successfully maintains a high concentration of phosphorylated eIF4E^{21–23}. Accordingly, eIF4E(S209A) MEFs were more refractory to infection with vaccinia virus or HSV-1 than were wild-type MEFs. These viruses also use many strategies to prevent the phosphorylation of the eukaryotic translation-initiation factor eIF2 α and are more resistant to type I interferon than are RNA viruses^{41,42}. Thus, phosphorylation of eIF4E represents another example of the strategies viruses use to control the type I interferon response by post-translational modification of critical host translation-initiation factors.

Our data have suggested that dephosphorylation of eIF4E acts as an arm of the host response to VSV and EMCV infection. In nature, the interaction between host defense mechanisms and viral countermeasures is balanced and results in limited acute viral replication and persistence in immunocompetent hosts. The S209A substitution of eIF4E distorted that balance by diminishing the synthesis of I κ B α , which resulted in more production of type I interferon. One possibility is that an antiviral mechanism does exist that diminishes the activity of eIF4E. Notably, natural mutations in the gene encoding eIF4E in some plants confer resistance to viral infection^{43,44}. Together our findings establish a previously unknown translation-control mechanism involved in the production of type I interferon, a fundamental aspect of innate host defense. Furthermore, they raise the possibility that interfering with the phosphorylation of eIF4E in virus-infected cells could be an additional means of augmenting the cellular innate immune response to viral infection.

METHODS

Methods and any associated references are available in the online version of the paper.

Note: Supplementary information is available in the online version of the paper.

ACKNOWLEDGMENTS

We thank A. Frey (NYU School of Medicine) for rat antibody immunoglobulin G; M. Olivier (McGill University) for tumor necrosis factor; J. Bell (University of Ottawa) for antibody to VSV proteins and VSV-GFP; J. Pelletier (McGill University) for the retroviral vectors MSCV-GFP and MSCV-eIF4E; M. Gale (University of Washington) for the PRDII luciferase reporter *I β nb1*PRDII-Luc; D.A. Muruve (University of Calgary) for the luciferase reporters *I β nb1*-pGL3 and *N β kbl*; R. Fukunaga (Kyoto University) for wild-type and Mnk1-Mnk2-deficient mice; J. Berlanga (Universidad Autónoma de Madrid) for Sindbis virus; and C. Lister for assistance. Supported by the Canadian Institutes of Health Research (MOP-7214 to N.S.), the US National Institutes of Health (AI 073898 and GM056927 to I.M., and T32 AI007647 to M.K.) and the Irma Hirschl Trust (I.M.).

AUTHOR CONTRIBUTIONS

B.H., M.J. and D.W. designed, did and analyzed experiments and wrote the manuscript; Y.V.S. and A.B.R. provided intellectual input and wrote the manuscript; M.K., T.A., N.R., I.T. and L.F. designed and did experiments; P.S., R.J.O.D., A.S., L.R. and J.H.F. contributed to experiments; R.C. critically reviewed the manuscript; M.C.-M. designed experiments and critically reviewed

the manuscript; M.O. and E.B. provided reagents; and I.M. and N.S. designed experiments and wrote the manuscript.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Published online at <http://www.nature.com/doi/10.1038/ni.2291>.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

- Katze, M.G., He, Y. & Gale, M. Jr. Viruses and interferon: a fight for supremacy. *Nat. Rev. Immunol.* **2**, 675–687 (2002).
- Kawai, T. & Akira, S. Antiviral signaling through pattern recognition receptors. *J. Biochem.* **141**, 137–145 (2007).
- Maniatis, T. *et al.* Structure and function of the interferon- β enhanceosome. *Cold Spring Harb. Symp. Quant. Biol.* **63**, 609–620 (1998).
- Silverman, N. & Maniatis, T. NF- κ B signaling pathways in mammalian and insect innate immunity. *Genes Dev.* **15**, 2321–2342 (2001).
- Hoffmann, A., Levchenko, A., Scott, M.L. & Baltimore, D. The I κ B-NF- κ B signaling module: temporal control and selective gene activation. *Science* **298**, 1241–1245 (2002).
- Chu, W.M. *et al.* JNK2 and IKK β are required for activating the innate response to viral infection. *Immunity* **11**, 721–731 (1999).
- Apostolou, E. & Thanos, D. Virus infection induces NF- κ B-dependent interchromosomal associations mediating monoallelic IFN- β gene expression. *Cell* **134**, 85–96 (2008).
- Honda, K., Takaoka, A. & Taniguchi, T. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. *Immunity* **25**, 349–360 (2006).
- Colina, R. *et al.* Translational control of the innate immune response through IRF-7. *Nature* **452**, 323–328 (2008).
- Gingras, A.C., Raught, B. & Sonenberg, N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. *Annu. Rev. Biochem.* **68**, 913–963 (1999).
- Duncan, R., Milburn, S.C. & Hershey, J.W. Heat shock effects on eIF-4F. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. *J. Biol. Chem.* **262**, 380–388 (1987).
- Joshi, B. *et al.* Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209. *J. Biol. Chem.* **270**, 14597–14603 (1995).
- Furic, L. *et al.* eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. *Proc. Natl. Acad. Sci. USA* **10**, 14134–14139 (2010).
- Ueda, T., Watanabe-Fukunaga, R., Fukuyama, H., Nagata, S. & Fukunaga, R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. *Mol. Cell. Biol.* **24**, 6539–6549 (2004).
- Morley, S.J. Intracellular signalling pathways regulating initiation factor eIF4E phosphorylation during the activation of cell growth. *Biochem. Soc. Trans.* **25**, 503–509 (1997).
- Waskiewicz, A.J., Flynn, A., Proud, C.G. & Cooper, J.A. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. *EMBO J.* **16**, 1909–1920 (1997).
- Huang, J.T. & Schneider, R.J. Adenovirus inhibition of cellular protein synthesis involves inactivation of cap-binding protein. *Cell* **65**, 271–280 (1991).
- Burgui, I., Yanguéz, E., Sonenberg, N. & Nieto, A. Influenza virus mRNA translation revisited: is the eIF4E cap-binding factor required for viral mRNA translation? *J. Virol.* **81**, 12427–12438 (2007).
- Kleijn, M., Vrins, C.L., Voorma, H.O. & Thomas, A.A. Phosphorylation state of the cap-binding protein eIF4E during viral infection. *Virology* **217**, 486–494 (1996).
- Connor, J.H. & Lyles, D.S. Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1. *J. Virol.* **76**, 10177–10187 (2002).
- Walsh, D. & Mohr, I. Phosphorylation of eIF4E by Mnk-1 enhances HSV-1 translation and replication in quiescent cells. *Genes Dev.* **18**, 660–672 (2004).
- Walsh, D. *et al.* Eukaryotic translation initiation factor 4F architectural alterations accompany translation initiation factor redistribution in poxvirus-infected cells. *Mol. Cell. Biol.* **28**, 2648–2658 (2008).
- Walsh, D., Perez, C., Notary, J. & Mohr, I. Regulation of the translation initiation factor eIF4F by multiple mechanisms in human cytomegalovirus-infected cells. *J. Virol.* **79**, 8057–8064 (2005).
- Arias, C., Walsh, D., Harbell, J., Wilson, A.C. & Mohr, I. Activation of host translational control pathways by a viral developmental switch. *PLoS Pathog.* **5**, e1000334 (2009).
- Both, G.W., Banerjee, A.K. & Shatkin, A.J. Methylation-dependent translation of viral messenger RNAs in vitro. *Proc. Natl. Acad. Sci. USA* **72**, 1189–1193 (1975).
- Scheper, G.C. *et al.* Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA. *J. Biol. Chem.* **277**, 3303–3309 (2002).
- Wendel, H.G. *et al.* Dissecting eIF4E action in tumorigenesis. *Genes Dev.* **21**, 3232–3237 (2007).

28. Topisirovic, I., Ruiz-Gutierrez, M. & Borden, K.L. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. *Cancer Res.* **64**, 8639–8642 (2004).
29. Banerjee, A.K. 5'-terminal cap structure in eucaryotic messenger ribonucleic acids. *Microbiol. Rev.* **44**, 175–205 (1980).
30. Jang, S.K. *et al.* A segment of the 5' nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during *in vitro* translation. *J. Virol.* **62**, 2636–2643 (1988).
31. Gitlin, L. *et al.* Essential role of mda-5 in type I IFN responses to polyriboinosinic: polyribocytidylic acid and encephalomyocarditis picornavirus. *Proc. Natl. Acad. Sci. USA* **103**, 8459–8464 (2006).
32. Honda, K. *et al.* IRF-7 is the master regulator of type-I interferon-dependent immune responses. *Nature* **434**, 772–777 (2005).
33. Huber, M.A. *et al.* The IKK-2/I κ B α /NF- κ B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in I κ B α -deficient mice. *J. Biol. Chem.* **277**, 1268–1275 (2002).
34. Warton, K., Foster, N.C., Gold, W.A. & Stanley, K.K. A novel gene family induced by acute inflammation in endothelial cells. *Gene* **342**, 85–95 (2004).
35. Visvanathan, K.V. & Goodbourn, S. Double-stranded RNA activates binding of NF- κ B to an inducible element in the human β -interferon promoter. *EMBO J.* **8**, 1129–1138 (1989).
36. Lenardo, M.J., Fan, C.M., Maniatis, T. & Baltimore, D. The involvement of NF- κ B in β -interferon gene regulation reveals its role as widely inducible mediator of signal transduction. *Cell* **57**, 287–294 (1989).
37. Zawatzky, R. & De Maeyer, E. De Maeyer-Guignard, J. Identification of individual interferon-producing cells by *in situ* hybridization. *Proc. Natl. Acad. Sci. USA* **82**, 1136–1140 (1985).
38. Hu, J. *et al.* Chromosome-specific and noisy IFNB1 transcription in individual virus-infected human primary dendritic cells. *Nucleic Acids Res.* **35**, 5232–5241 (2007).
39. Neznanov, N. *et al.* Proteolytic cleavage of the p65-RelA subunit of NF- κ B during poliovirus infection. *J. Biol. Chem.* **280**, 24153–24158 (2005).
40. Wang, X. *et al.* Influenza A virus NS1 protein prevents activation of NF- κ B and induction of $\alpha\beta$ interferon. *J. Virol.* **74**, 11566–11573 (2000).
41. Cheng, G., Feng, Z. & He, B. Herpes simplex virus 1 infection activates the endoplasmic reticulum resident kinase PERK and mediates eIF-2 α dephosphorylation by the gamma(1)34.5 protein. *J. Virol.* **79**, 1379–1388 (2005).
42. He, B., Gross, M. & Roizman, B. The γ_1 34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1 α to dephosphorylate the α subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. *Proc. Natl. Acad. Sci. USA* **94**, 843–848 (1997).
43. Piron, F. *et al.* An induced mutation in tomato eIF4E leads to immunity to two potyviruses. *PLoS ONE* **5**, e11313 (2010).
44. German-Retana, S. *et al.* Mutational analysis of plant cap-binding protein eIF4E reveals key amino acids involved in biochemical functions and potyvirus infection. *J. Virol.* **82**, 7601–7612 (2008).

ONLINE METHODS

Chemicals and antibodies. Chemicals, poly(I:C) and poly(dI:dC) were from Sigma. FuGENE 6 and RNaseIN were from Roche. Tumor necrosis factor was a gift from M. Olivier (McGill University). [³⁵S]methionine-[³⁵S]cysteine and [³²P]dATP were from PerkinElmer. Antibodies were as follows: anti-eIF4E (610270; 87; BD Biosciences); anti-β-actin (A5316; AC-74; Sigma); anti-IκBα (4812; Cell Signaling); antibody to phosphorylated eIF4E (NB 100-2234; Novus Biologicals); control rat antibody immunoglobulin G (a gift from A. Frey); neutralizing antibody to mouse IFN-α (22100-1; RMMMA-1), IFN-β (22400-1; RMMB-1) or IFN-γ (22500-1; RMMG-1; all from PBL Biomedical Laboratories); goat immunoglobulin G antibody to mouse (AF784) and neutralizing anti-IL-1β (AB-401-NA; both from R&D Systems); polyclonal antibody to vaccinia virus (8101; Virostat); and antibody to VSV proteins (a gift from J. Bell). Superscript III reverse transcriptase was from Invitrogen. The retroviral vectors MSCV-GFP (empty vector control) and MSCV-eIF4E²⁷ were provided by J. Pelletier. The shRNA lentiviral plasmids were from Sigma (pLKO.1-puro control shRNA and IκBα shRNA clone 939 (5'-CCGGGAGTCAGAATTCACAGAGGATCTCGAGATCCTGTGAATTCTGACTCTTTTGG-3'). The PRDII luciferase reporter *Ifnb1*PRDII-Luc was provided by M. Gale. The *Ifnb1*-pGL3 and *Nfkb1*-luciferase reporters were provided by D.A. Muruve.

Cells, mice and viruses. Mice were kept in pathogen-free housing. Research involving animals was done according to the regulations of the Canadian Council of Animal Care and with the approval of the McGill University Animal Care Committee. Wild-type and eIF4E(S209A) mice and MEFs have been described¹³. Mice were backcrossed seven times onto a pure BALB/c background. Mice were born at normal Mendelian ratios and developed normally. Wild-type and Mnk1-Mnk2-deficient mice were from R. Fukunaga¹⁴. BHK21, Vero cells and BSC40 cells were from the American Type Culture Collection. The Indiana serotypes of VSV and EMCV have been described^{45,46}. Sindbis virus was a gift from J. Berlanga. VSV-GFP was from J. Bell. Vaccinia virus (Western Reserve strain)²² and HSV-1 Us11-GFP have been described⁴⁷.

Viral infection and metabolic radiolabeling. Viral infection and metabolic radiolabeling of cells have been described⁴⁶. For *in vivo* experiments, female BALB/c mice were anesthetized with 2 μl rodent 'cocktail' (5 ml ketamine, 2.5 ml xylazine, 1 ml acepromazine and 1.5 ml sterile saline) per 1 g body weight and were infected intranasally with VSV at a dose of 1 × 10⁴ PFU per mouse. Mice were monitored for 12 d after infection and were killed when hindlimb paralysis developed. Blood was collected 48 h after infection by cardiac puncture and the serum concentration of IFN-β was determined by B16-Blue assay (InvivoGen).

Rescue experiments. The retroviral vector MSCV-IRES-GFP (empty vector control) or MSCV-eIF4E-IRES-GFP²⁷ was transfected into phoenix-293-T packaging cells. Virus-containing medium was used for infection of eIF4E(S209A) MEFs. Cells were sorted by flow cytometry for expression of green fluorescent protein after 48 h.

Isoelectric focusing. Vertical-slab isoelectric focusing was done as described²¹.

Plaque assays. Plaque assays were done as described with confluent monolayers of BHK-21 or Vero cells⁴⁶. Titers of vaccinia virus were determined as described²².

Poly(I:C) treatment, virus-infection-protection assay and enzyme-linked immunosorbent assay. Wild-type and eIF4E(S209A) MEFs were seeded at a density of 0.7 × 10⁵ cells per well. Cells were treated for 6 h with the appropriate concentration of poly(I:C) through the use of the FuGENE 6 transfection reagent according to the manufacturer's protocol (Roche). Cells were lysed and total RNA was isolated, followed by reverse transcription and semiquantitative PCR. The intensity of bands was quantified with ImageJ software. Conditioned supernatants were collected and the production of mouse IFN-β was detected by enzyme-linked immunosorbent assay according to the manufacturer's protocol (PBL Biomedical Laboratories). For measurement of antiviral activity,

wild-type cells were overlaid for 24 h with conditioned cell medium and were infected for 17–24 h with VSV at an MOI of 0.1 PFU/cell.

Polysome profiles. Cells from five plates 15 cm in diameter at ~80% confluence were used for the preparation of polysomal fractions as described⁹. RNA was isolated from half of each fraction with TRIzol reagent (Invitrogen).

RNA extraction and semiquantitative RT-PCR. RNA was extracted from 0.7 × 10⁵ cells with an RNeasy Mini Kit according to the manufacturer's protocol (Qiagen). Superscript III reverse transcriptase, oligo(dT) and 1 μg of total RNA or RNA of polysomal fractions was used according to the manufacturer's protocol (Invitrogen) for reverse transcription. Each cDNA template (1 μl) was analyzed by semiquantitative PCR with specific primers and Taq DNA polymerase according to the supplier's protocol (Fermentas). The reaction products were in quantifiable range, as determined by serial dilution of mRNA isolated from the cytoplasmic fraction of wild-type MEFs. Primers for *Ifnb*, *Irf7* or *Actb* have been described⁹. Primers for *Ifeh1*, *Nfkb1a* and VSV-specific M protein were as follows: *Ifeh1* sense (TGTCTGTTCTGCAGAGGACAGCTT) and antisense (ACAGAAAGATGAGGTGGTCCAGCA); *Nfkb1a* sense (GACGCAGACCTGCACACCCC) and antisense (TGGAGGGCTGTCCGGCCATT); and M protein sense (GTGGCAGCCGCTGTATCCCAT) and anti-sense (CGCAGTGAGCGTGATACTCGGG).

Preparation of nuclear extracts and EMSA. Lungs of mice infected with VSV were isolated and nuclear proteins were extracted as described⁴⁸. Cells grown to a confluence of ~70% in a dish 10 cm in diameter were treated for the appropriate time with tumor necrosis factor (1 ng/ml). Nuclear extracts were prepared and EMSA was done as described⁴⁹. Nuclear extracts were incubated with [³²P]dATP-radiolabeled oligonucleotides containing a consensus binding site for NF-κB-c-Rel homodimer and heterodimeric complexes (5'-AGTTGAGGGGACTTCCAGGC-3'; Santa Cruz Biotechnology) or containing a consensus binding site for AP-1-c-Jun homodimer and Jun-Fos heterodimeric complexes (5'-CGCTTGATGACTCAGCCGGAA-3'; Santa Cruz Biotechnology) or a consensus binding site for SP1 (5'-ATTGATCGGGGCGGGGCGAGC-3'). DNA-protein complexes were resolved from free-labeled DNA by electrophoresis through native 4% (wt/vol) polyacrylamide gels and the dried gels were analyzed by autoradiography.

Cytokine assay. Supernatants of wild-type or eIF4E(S209A) MEFs (1 × 10⁵ cells) were analyzed by the MILLIPLEX MAP Mouse Cytokine/Chemokine according to the manufacturer's protocol (Millipore) 8 h after being seeded.

Luciferase reporter assays. Plasmid DNA (1 μg) and the renilla luciferase plasmid pRL-TK (0.01 μg) were transfected into 3 × 10⁵ cells in a six-well plate through the use of Lipofectamine 2000 (Invitrogen). *In vitro*-transcribed EMCV-IRES-firefly luciferase⁴⁶ mRNA (0.5 μg) was transfected together with capped-renilla luciferase mRNA (0.05 μg) into 3 × 10⁵ cells. Luciferase activity was measured 48 h after transfection of plasmids or 3 h after transfection of mRNA as described⁹.

Metabolic labeling and TCA precipitation. Wild-type and eIF4E(S209A) MEFs were grown for 2 h in methionine- and cysteine-free medium supplemented with 10% dialyzed serum. The medium was replaced with methionine-free DMEM containing ³⁵S protein-labeling mix (10 μCi/ml) and 1% FBS. After 30 min, cell monolayers were lysed and the radioactivity incorporated into material insoluble in 5% trichloroacetic acid was measured. Total protein content was determined with a Bio-Rad Protein Assay. Incorporation was normalized to protein content and is presented as counts per minute.

Nitric oxide production. Macrophages isolated from the bone marrow of B10A.Bcgr (Bacillus-Calmette-Guérin-resistant) mice (B10R cell line) were stimulated for 24 h with the appropriate treatment. The production of nitric oxide was assessed by measurement of the accumulation of nitrites in the cell culture medium with the colorimetric Griess Reagent System according to the manufacturer's protocol (Promega).

Statistical analysis. GraphPad Prism statistical software, version 4.0, was used for statistical analysis. *P* values of 0.01 to 0.05 were considered significant.

45. Stojdl, D.F. *et al.* The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. *J. Virol.* **74**, 9580–9585 (2000).
46. Svitkin, Y.V. *et al.* Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation. *Mol. Cell. Biol.* **25**, 10556–10565 (2005).
47. Benboudjema, L., Mulvey, M., Gao, Y., Pimplikar, S.W. & Mohr, I. Association of the herpes simplex virus type 1 Us11 gene product with the cellular kinesin light-chain-related protein PAT1 results in the redistribution of both polypeptides. *J. Virol.* **77**, 9192–9203 (2003).
48. Liu, S.F., Ye, X. & Malik, A.B. In vivo inhibition of nuclear factor- κ B activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. *J. Immunol.* **159**, 3976–3983 (1997).
49. Jaramillo, M., Naccache, P.H. & Olivier, M. Monosodium urate crystals synergize with IFN- γ to generate macrophage nitric oxide: involvement of extracellular signal-regulated kinase 1/2 and NF- κ B. *J. Immunol.* **172**, 5734–5742 (2004).